Press Room

A new report by the American Cancer Society Cancer Action Network (ACS CAN) found that over 70% of commercially-insured patients encountered out-of-pocket expenses for follow-up breast cancer diagnostic tests in 2023. These follow-up tests, such as a diagnostic mammogram, MRI, ultrasound or biopsy, are medically recommended next steps to determine if an individual may or may not have cancer; however, barriers like cost can keep people from getting them.

The following is a statement from American Cancer Society Cancer Action Network (ACS CAN) Pennsylvania Government Relations Director Donna Greco:

“In 2024, ACS CAN was proud to see the Pennsylvania Legislature mobilize swiftly and in a bipartisan manner to bring the promise of precision medicine to more patients. Beginning in the new year, Act 39 of 2024 will make it so that all patients who can benefit and are insured through a state-regulated health plan will receive coverage for biomarker testing, a game changer in the fight against cancer and an essential step in accessing precision medicine treatments. Pennsylvanians also secured a victory for access to care through Act 42 of 2024, the newly enacted legislation that includes telemedicine as a covered benefit in the Commonwealth.

Harrisburg residents and cancer advocates gathered at the Pennsylvania War Veterans’ Memorial Fountain outside of the Capitol building in Harrisburg this evening to honor the lives affected by cancer with a heartfelt display of 270 Lights of Hope bags representing the estimated 27,000 Pennsylvanians who will die from the disease in 2024. The personalized Lights of Hope bags were lined along the fountain, which was lit pink for Breast Cancer Awareness Month, to symbolize the strength, hope and memories of those touched by cancer.

Senator Devlin Robinson received the National Distinguished Advocacy Award this week, the most prestigious award presented by the American Cancer Society Cancer Action Network (ACS CAN), in recognition of his significant contribution in the fight against cancer. 

A recent poll by the American Cancer Society Cancer Action Network (ACS CAN) shows 8 in 10 (86%) Pennsylvania voters view a candidate’s position on access to affordable, comprehensive health coverage as a vote-determining factor.

The Pennsylvania Legislature passed and Governor Shapiro certified the 2024-25 budget—the contents of which reflect a step in the right direction in the effort to end cancer as we know it for everyone.

Today, Governor Shapiro signed House Bill 1754 into law, securing a major win for patients across Pennsylvania. The new law will require all state-regulated health plans, including Medicaid, to cover comprehensive biomarker testing, which will enable more Pennsylvanians to access biomarker testing that can open the door to precision medicine. Targeted treatment can lead to fewer side effects, improved survival, better quality of life and potentially lower costs for patients facing cancer and other serious illnesses.  

Earlier today, the Pennsylvania State Senate unanimously passed House Bill 1754, the bipartisan proposal to increase access to biomarker testing. The bill will now go to Governor Shapiro’s desk, providing him the opportunity to ensure coverage of this essential testing for more Pennsylvanians. The American Cancer Society Cancer Action Network (ACS CAN) and the PA Biomarker Testing Coalition are advocating for this significant policy change to ensure more cancer patients and people with other illnesses and diseases can get the testing needed to access precision medicine. 

Earlier this morning, House Bill 1754 was voted out of the Senate Banking & Insurance Committee. This legislation, which aims to ensure that biomarker testing is covered by Medicaid and all other state-regulated insurance plans when patients need it, now advances to the Senate floor for consideration.

This afternoon, the Pennsylvania State House passed legislation that would ensure biomarker testing is covered by more insurance plans, including Medicaid, when patients need it.